DRREDDY

Dr. Reddy’s continues to impress with its steady US generics performance and strong pipeline in biosimilars. The company has maintained healthy margins, supported by new launches and cost control. Expansion into complex generics and emerging markets adds long-term visibility. With a strong balance sheet and focus on innovation, Dr. Reddy’s remains well-placed to benefit from global pharmaceutical opportunities. Investors see it as a solid defensive play with consistent earnings and sustainable growth potential.